Conchita Vens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6515149/publications.pdf

Version: 2024-02-01

31 papers	1,611 citations	430874 18 h-index	501196 28 g-index
32 all docs	32 docs citations	32 times ranked	3051 citing authors

#	Article	IF	Citations
1	Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development. Molecular Cancer Therapeutics, 2021, 20, 1614-1626.	4.1	12
2	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 1256-1266.	7.0	20
3	Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy. Radiotherapy and Oncology, 2020, 147, 186-194.	0.6	12
4	Ovarian cancerâ€derived copy number alterations signatures are prognostic in chemoradiotherapyâ€treated head and neck squamous cell carcinoma. International Journal of Cancer, 2020, 147, 1732-1739.	5.1	6
5	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. PLoS ONE, 2020, 15, e0232639.	2.5	35
6	Title is missing!. , 2020, 15, e0232639.		0
7	Title is missing!. , 2020, 15, e0232639.		0
8	Title is missing!. , 2020, 15, e0232639.		0
9	Title is missing!. , 2020, 15, e0232639.		0
10	Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC. Cancer Research, 2019, 79, 5597-5611.	0.9	28
11	Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients. Cancers, 2019, 11, 583.	3.7	28
12	Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models. Radiotherapy and Oncology, 2019, 138, 17-24.	0.6	3
13	Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy. Cancers, 2019, 11, 445.	3.7	30
14	Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation. Frontiers in Oncology, 2019, 9, 1470.	2.8	19
15	Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer. Oral Oncology, 2018, 81, 35-44.	1.5	45
16	Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials. Radiotherapy and Oncology, 2018, 126, 443-449.	0.6	17
17	Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association. PLoS ONE, 2018, 13, e0206632.	2.5	2
18	DNA Repair Molecular Beacon assay: a platform for real-time functional analysis of cellular DNA repair capacity. Oncotarget, 2018, 9, 31719-31743.	1.8	21

#	Article	IF	Citations
19	Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. Oncotarget, 2018, 9, 18198-18213.	1.8	37
20	Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity. Oncotarget, 2017, 8, 73925-73937.	1.8	21
21	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiotherapy and Oncology, 2015, 116, 358-365.	0.6	115
22	Strategies to improve radiotherapy with targeted drugs. Nature Reviews Cancer, 2011, 11, 239-253.	28.4	889
23	Targeting Base Excision Repair as a Sensitization Strategy in Radiotherapy. Seminars in Radiation Oncology, 2010, 20, 241-249.	2.2	34
24	Targeted Radiosensitization of Cells Expressing Truncated DNA Polymerase Î². Cancer Research, 2010, 70, 8706-8714.	0.9	34
25	Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective. Drug Resistance Updates, 2010, 13, 29-43.	14.4	66
26	Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair, 2009, 8, 336-346.	2.8	30
27	Cell cycle phase dependent role of DNA polymerase Î² in DNA repair and survival after ionizing radiation. Radiotherapy and Oncology, 2008, 86, 391-398.	0.6	16
28	Involvement of DNA Polymerase Beta in Repair of Ionizing Radiation Damage as Measured byIn VitroPlasmid Assays. Radiation Research, 2007, 168, 281-291.	1.5	11
29	Role for DNA polymerase beta in response to ionizing radiation. DNA Repair, 2007, 6, 202-212.	2.8	18
30	Radiosensitization by a dominant negative to DNA polymerase Î² is DNA polymerase Î²-independent and XRCC1-dependent. Radiotherapy and Oncology, 2005, 76, 123-128.	0.6	25
31	The role of DNA polymerase beta in determining sensitivity to ionizing radiation in human tumor cells. Nucleic Acids Research, 2002, 30, 2995-3004.	14.5	32